Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 4Genitourinary 3Breast 3Thoracic 2Dermatologic 2Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1CNS 1

Conditions

Melanoma 7Rectal Neoplasms 2Pancreatic Neoplasms 2Neoplasms 2Colonic Neoplasms 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Teratoma 1Stomach Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma 1Lung Neoplasms 1Hematologic Neoplasms 1Glioma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1

Interventions

pembrolizumab 6cemiplimab 3Cyclophosphamide 3temsirolimus 2palbociclib 2cediranib 2Therapeutics 2Radiotherapy 2Radiosurgery 2Psychiatric Rehabilitation 2Paclitaxel 2Oxaliplatin 2Nivolumab 2Methods 2Magnetic Resonance Spectroscopy 2Leucovorin 2Gemcitabine 2Fluorouracil 2Drug Therapy 2Docetaxel 2Cisplatin 2Capecitabine 2Biological Therapy 22,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1tanespimycin 1sonidegib 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Colonic Neoplasms × palbociclib × Dermatologic × Clear all
NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT01037790 2021-03-11

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

Abramson Cancer Center at Penn Medicine

Phase 2 Completed
304 enrolled 12 charts
BreastDermatologicGastrointestinalGenitourinary

Breast Neoplasms, Colonic Neoplasms, Melanoma, Rectal Neoplasms, Teratoma, Testicular Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡